Clonidine Suppression Test: Diagnosis of Pheochromocytoma
The clonidine suppression test is used to diagnose pheochromocytoma when plasma or urinary catecholamines/metanephrines are only modestly elevated, helping to distinguish true disease from false-positive results. 1
Clinical Context and Indication
Pheochromocytoma is a rare catecholamine-secreting tumor (0.2-0.4% of hypertensive cases) that presents with stable or paroxysmal hypertension, often accompanied by headache, sweating, palpitations, and pallor. 1 The primary diagnostic approach involves measuring plasma free metanephrines (97-98% sensitivity) or urinary fractionated metanephrines. 1
The clonidine suppression test should be performed specifically when:
- Plasma or urine catecholamine/metanephrine values are only modestly elevated (typically 1.7-fold to 4-fold above upper reference limit) 2, 3
- Strong clinical suspicion of pheochromocytoma persists despite borderline biochemical results 1
- Differentiation between endogenous catecholamine hypersecretion and false-positive results is needed 4
Test Interpretation
The test is considered negative (excluding pheochromocytoma) when there is a marked reduction of plasma catecholamines after clonidine administration. 1
Specific Diagnostic Criteria
The most recent high-quality evidence establishes optimal cutoffs:
- Normetanephrine suppression to <80% of age-related upper limit of normal provides 94% sensitivity and 97% specificity 3
- Traditional criteria (normetanephrine ≥112 ng/L and <40% suppression) yield 88% sensitivity and 97% specificity 3
- For urinary testing: ≥50% reduction in norepinephrine AND ≥15% reduction in normetanephrine provides 93.3% sensitivity for both parameters 5
The clonidine suppression test demonstrates 100% specificity in correctly identifying false-positive normetanephrine results, making it highly reliable for excluding disease. 2 When plasma normetanephrine is elevated at baseline, the test correctly identifies all patients without pheochromocytoma. 2
Important Caveats and Limitations
The test has limited utility for isolated metanephrine (epinephrine metabolite) elevations, as sensitivity drops from 94% to 85% when tumors with isolated metanephrine increases are included. 2 Clonidine does not significantly suppress epinephrine or metanephrine in either disease or non-disease states. 5
False-negative results can occur in patients with small pheochromocytomas, though this is uncommon (sensitivity 94%). 3 The test should not be used as first-line screening but rather as a confirmatory tool after initial biochemical testing. 1
Clinical Utility in Special Populations
The test maintains diagnostic accuracy in patients taking interfering medications and those with borderline initial testing results. 5 It is particularly valuable in neurofibromatosis type 1 patients, who have higher pheochromocytoma rates and frequently encounter false-positive screening results. 6
When both norepinephrine and normetanephrine suppression criteria are concordant, diagnostic accuracy reaches 100% sensitivity and 92% specificity. 5
Contraindication
In hypertension caused by pheochromocytoma, clonidine (as a therapeutic agent) produces no therapeutic effect and should not be used for blood pressure management. 7 However, this does not contraindicate its use as a diagnostic suppression test.